Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic ...

Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study Highlights Company’s Leadership and Progress in Developing ...

Be Biopharma, Inc. ("Be Bio"), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that an abstract relating to its BCM platform has been accepted for oral ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third ...

In their latest earnings report for the third quarter of 2024, TScan Therapeutics highlighted key milestones, including plans for an oral presentation at the upcoming ... with plans to open expansion ...

In an oral presentation today, the company shared continued progress ... EVEREST-1 is a first-in-human, phase 1/2, multicenter, open label, nonrandomized study to evaluate the safety and efficacy of a ...

Academia should provide the sanctuary of shared purpose, especially in my field of disaster medicine, which presumes everyone ...

The International Court of Justice has released the detailed schedule for oral arguments in its advisory opinion on the Obligations of States in respect of Climate Change ...

The Warren Alpert Medical School held its 18th annual Academic Symposium Wednesday afternoon. The symposium was the largest ...